Probatebeta
Target

ERBB2

Receptor tyrosine-protein kinase erbB-2

As of the edition of 20 October 2026, ERBB2 (receptor tyrosine-protein kinase erbB-2, UniProt P04626) has 58 drugs tested at it and 61 companies on the list, 19 on route A and 9 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P04626
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
63
Disease areas
Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Hormones; Nervous system
Registered trials of its drugs
1,728

Drugs at this target

StatusCount
Marketed12
Active17
Went quiet8
Stopped16
Status not established5
Total58
DrugStatusFurthest phaseUS protection
TrastuzumabMarketedPhase 4Ended 2017
PertuzumabMarketedPhase 4Ended 2024
PyrotinibActivePhase 4none listed
Trastuzumab deruxtecanMarketedPhase 4Ends 2031
Trastuzumab emtansineMarketedPhase 4Ended 2025
VandetanibMarketedPhase 3none listed
Disitamab vedotinActivePhase 4none listed
TucatinibMarketedPhase 4Ends 2034
ZanidatamabMarketedPhase 3Ends 2036
PoziotinibStoppedPhase 3none listed
RC48-ADCActivePhase 3none listed
ZongertinibMarketedPhase 3Ends 2041

12 of 58 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A19
Route B9
Engaged26
Undetermined7
Total on the list61
Three companies on route A or B, with the route only
CompanyRoute
TaihoRoute A
MacroGenicsRoute B
AstraZenecaRoute B

The other 58 companies at ERBB2

In the product

61 companies in all; 58 are not named here, and no score is.

See the 61 companies at ERBB2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at ERBB2

Other targets in cancer

Companies holding approvals at ERBB2